Shafran JS - Search Results

1

BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.

Andrieu GP, Shafran JS, Smith CL, Belkina AC, Casey AN, Jafari N, Denis GV. Andrieu GP, et al. Among authors: shafran js. Cancer Lett. 2019 Nov 28;465:45-58. doi: 10.1016/j.canlet.2019.08.013. Epub 2019 Aug 29. Cancer Lett. 2019. PMID: 31473251 Free PMC article.

2

BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.

Andrieu GP, Shafran JS, Deeney JT, Bharadwaj KR, Rangarajan A, Denis GV. Andrieu GP, et al. Among authors: shafran js. J Leukoc Biol. 2018 Aug;104(2):265-274. doi: 10.1002/JLB.5RI0917-380RR. Epub 2018 Mar 1. J Leukoc Biol. 2018. PMID: 29493812 Free PMC article. Review.

3

BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.

Shafran JS, Andrieu GP, Györffy B, Denis GV. Shafran JS, et al. Mol Cancer Res. 2019 Aug;17(8):1627-1638. doi: 10.1158/1541-7786.MCR-18-1279. Epub 2019 May 20. Mol Cancer Res. 2019. PMID: 31110158 Free PMC article.

4

BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.

Shafran JS, Jafari N, Casey AN, Győrffy B, Denis GV. Shafran JS, et al. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):268-277. doi: 10.1038/s41391-020-0246-y. Epub 2020 Jul 21. Prostate Cancer Prostatic Dis. 2021. PMID: 32690869 Free PMC article.

5

Adipocyte-derived exosomes may promote breast cancer progression in type 2 diabetes.

Jafari N, Kolla M, Meshulam T, Shafran JS, Qiu Y, Casey AN, Pompa IR, Ennis CS, Mazzeo CS, Rabhi N, Farmer SR, Denis GV. Jafari N, et al. Among authors: shafran js. Sci Signal. 2021 Nov 23;14(710):eabj2807. doi: 10.1126/scisignal.abj2807. Epub 2021 Nov 23. Sci Signal. 2021. PMID: 34813359 Free PMC article.

6

Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.

Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Mori JO, et al. Among authors: shafran js. Prostate. 2022 Jun;82(10):1005-1015. doi: 10.1002/pros.24351. Epub 2022 Apr 11. Prostate. 2022. PMID: 35403746 Review.

7

Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.

Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes DB, Patnaik A. Chaudagar K, et al. Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350. Clin Cancer Res. 2023. PMID: 36862086 Free PMC article.

8

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.

Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Chaudagar K, et al. Clin Cancer Res. 2023 Dec 1;29(23):4930-4940. doi: 10.1158/1078-0432.CCR-23-1441. Clin Cancer Res. 2023. PMID: 37721526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page